Thomas Jefferson University

Jefferson Digital Commons
Rothman Institute Faculty Papers

Rothman Institute

6-1-2014

Aquacel Surgical Dressing Reduces the Rate of Acute PJI
Following Total Joint Arthroplasty: A Case-Control Study.
Jenny Cai
The Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Joseph A Karam
The Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Javad Parvizi
The Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Eric B Smith
The Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Peter F. Sharkey
The Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Follow this and additional works at: https://jdc.jefferson.edu/rothman_institute
Part of the Orthopedics Commons

Let us know how access to this document benefits you
Recommended Citation
Cai, Jenny; Karam, Joseph A; Parvizi, Javad; Smith, Eric B; and Sharkey, Peter F., "Aquacel
Surgical Dressing Reduces the Rate of Acute PJI Following Total Joint Arthroplasty: A CaseControl Study." (2014). Rothman Institute Faculty Papers. Paper 47.
https://jdc.jefferson.edu/rothman_institute/47
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Rothman Institute Faculty Papers by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

1

As submitted to:

2

The Journal of Arthroplasty

3

And later published as:

4

Aquacel Surgical Dressing Reduces the Rate of Acute PJI Following

5

Total Joint Arthroplasty: A Case–Control Study

6

Volume 29, Issue 6, pages: 1098-100

7

DOI: 10.1016/j.arth.2013.11.012

8

June 2014

9

1

10
11

Abstract
An effort to prevent PJI has led to the development of antimicrobial dressings that

12

support wound healing. We sought to determine whether Aquacel Surgical dressing

13

independently reduces the rate of acute PJI following TJA. A single institution retrospective

14

chart review of 903 consecutive cases who received the Aquacel Surgical dressing and 875

15

consecutive cases who received standard gauze dressing was conducted to determine the

16

incidence of acute PJI (within 3 months). The incidence of acute PJI is 0.44% in the Aquacel

17

dressing group compared to 1.7% in the standard gauze dressing group (P = 0.005). Multivariate

18

analysis revealed that use of Aquacel dressing was an independent risk factor for reduction of PJI

19

(odds ratio of 0.165, 95% conﬁdence interval: 0.051–0.533). Aquacel Surgical dressing

20

signiﬁcantly reduces the incidence of acute PJI.

21
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Introduction
Periprosthetic joint infection (PJI) is one of the most dreaded complications that occur

24

after total joint arthroplasty (TJA). PJI is reported to occur in 1%–4% and 0.59%–2%of patients

25

who have undergone total knee and hip arthroplasty, respectively [1,2]. The infection causes

26

physical, emotional, and ﬁnancial strain to patients and their families as well as an immense

27

monetary burden to hospitals and our economy. The annual nationwide cost to control infection

28

is approximately $250 million. The cost of treating an individual PJI can be in excess of $50,000

29

and if the offending organism is antibiotic resistant, i.e. MRSA, that cost can surpass $100,000

30

[3,4]. Additionally, perioperative mortality associated with PJI can be 10 times greater than with

31

primary TJA [5,6].

32

Eradication of infection often requires additional surgery and is distressful for both the

33

treating physician and patient. While there are numerous possible causes for PJI, a few important

34

risk factors related to the wound itself have been identiﬁed including wound drainage and

35

superﬁcial wound infections [7]. The traditional approach to wound care consists of a simple

36

dressing that could be removed after 1 or 2 days with the idea that the wound re-epithelializes

37

during that time and can then be left uncovered.[8]. Among efforts to prevent the occurrence of

38

PJI, commercial dressings have been developed to optimize wound healing, seal wound drainage

39

and have antimicrobial properties [9]. In contrast to the conventional use of standard gauze

40

bandages, these dressings feature antimicrobial linings and have shown to decrease surgical site

41

infection rates [10].

42

The Aquacel Ag Hydroﬁber dressing is an antimicrobial dressing that consists of a

43

weaved cellulose center that contours to the skin to eliminate dead space, absorbs exudates,

44

releases ionic silver to reduce microbial activity and supports wound healing [11]. Furthermore,
3

45

the dressing seals the wound and prevents seepage of drainage beyond the dressing perimeter.

46

The objective of this study was to evaluate the effect of using this dressing on the occurrence of

47

acute PJI in patients undergoing TJA. We hypothesized that the Aquacel Ag Hydroﬁber dressing

48

would support healing following surgery and possibly reduce the rate of acute PJI.

49
50

Methods

51

Prior to initiation of the study, institutional review board approval was obtained. Using

52

our computerized joint arthroplasty database, 950 consecutive patients who underwent primary

53

total hip or total knee arthroplasty between October 2010 and March 2012 and received the

54

Aquacel dressing were identiﬁed. A list of 950 consecutive patients who received standard

55

dressings and who were admitted to the hospital before implementing systematic use of the

56

Aquacel dressing from April 2007 to August 2010 was generated in a similar fashion. To allow

57

for consistency in the use of the new dressing, data from the initial 6 weeks when Aquacel

58

dressing was utilized were omitted. Exclusion criteria included hip hemiarthroplasty,

59

unicompartmental knee arthroplasty, TJA for fracture treatment, conversion TJA, and revision

60

TJA. Each case was reviewed to verify the exclusion criteria and collect demographic

61

information, medical comorbidities, intraoperative parameters and development of acute PJI. The

62

latter was defined as PJI occurring within 3 months of surgery based on the new definition

63

criteria established by the Musculoskeletal Infection Society [12]. After eliminating patients

64

based on the exclusion criteria, 903 patients with hip (392), knee (508) or hip and knee (3)

65

arthroplasties were retained in the Aquacel group and 875 patients with hip (376) or knee (499)

66

arthroplasty in the standard dressing group. The Aquacel dressing was applied on the surgical

67

site in sterile conditions in the operating room and kept in place for 5 days postoperatively.
4

68

Standard dressing application consisted of sterile xeroform and gauze applied over the incision

69

site in the operating room and wrapped in an ace bandage that remained in place for 2 days

70

postoperatively.

71

In addition to the application of the Aquacel Surgical dressing, changes in clinical

72

practice during the study period included the use of dual intravenous antibiotic prophylaxis with

73

vancomycin and cefazolin (vs. cefazolin alone previously) and systematic irrigation with dilute

74

betadine before wound closure. These changes occurred 9 and 4 months before the end of the

75

study period respectively. A total of 37 patient-related and procedure-related risk factors were

76

taken into account in a multivariate analysis model where the dependent variable was the

77

development of acute PJI (Table 1). Statistical analyses were performed using R version 2.15.1

78

(R Foundation for Statistical Computing, Vienna, Austria).

79
80
81

Results
The prevalence of acute PJI was lower in the Aquacel group (0.44%) compared to the

82

standard dressing group (1.71%). Bivariate analysis conducted with Fisher's test first showed this

83

to be statistically significant (P = 0.005). A backward stepwise logistic regression model retained

84

7 independent risk factors for PJI (of 37 variables), including the use of Aquacel dressing, with

85

an independent odds ratio of 0.165 (95% confidence interval: 0.051–0.533). Other independent

86

significant risk factors for infection were as follows: older age, higher body mass index, smoking

87

status, thyroid disease, liver disease and history of steroid treatment (Table 2). Notably,

88

utilization of vancomycin prophylaxis and betadine irrigation were not shown to be significant

89

independent protective factors for acute PJI.

90
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91
92

Discussion
PJI is a major healthcare concern with mental, physical and financial burden on affected

93

patients. With projected exponential increases in its incidence and costs, and the predicted

94

reforms of healthcare reimbursement, prevention of this complication is gaining more

95

importance [13]. Wound healing problems and superficial surgical site infections have

96

consistently shown to be determining risk factors for the development of PJI [14,15]. Thus,

97

addressing these specific issues may prevent the occurrence of deep infection. The Aquacel

98

dressing has several features that could positively affect the wound environment: it sequesters

99

fluid to avoid tissue maceration, while at the same time releasing a gel that maintains a relatively

100

humid environment; it is also completely impermeable, preventing bacteria from entering the

101

wound site from the outside environment and maintaining hypoxia in the wound, which has been

102

shown to enhance healing and cellular immunity through the up-regulation of hypoxic-inducible

103

factors [16]. The addition of silver provides antimicrobial activity [17].

104

The use of the Aquacel dressing in TJA has previously been shown to create less need for

105

dressing changes, thus decreasing burden on healthcare personnel, diminishing superficial wound

106

problem, and avoiding delays in hospital discharge due to wound healing issues [18]. As the first

107

study to correlate Aquacel dressing with acute PJI, our results show that this dressing is an

108

effective measure to significantly reduce the occurrence of acute PJI after TJA, when compared

109

to standard dressings with gauze and tape. In our series, it independently reduced the rate of

110

acute PJI approximately sixfold.

111

The cost of one standard Aquacel dressing at our institution is $39.05. The cost to treat a

112

PJI has been variably estimated to range from $50,000 to over $100,000 [13]. A standard taped

113

surgical gauze dressing costs approximately $5.00. Therefore, the additional cost per case for an
6

114

Aquacel dressing is about $34.00. Infection after TJA has been reported to have an incidence

115

ranging from 1.0% to 2.0% [4]. In the United States., there are over 1,000,000 TKAs and THAs

116

performed annually [19]. Assuming the lowest cost ($50,000) of PJI treatment and the lower

117

incidence (1%) of reported PJI, the annual costs to manage PJI in the United States likely exceed

118

$500,000,000. The cost of using an Aquacel dressing routinely in the United States after TJA

119

would add approximately $27,000,000 in cost. If the reported fourfold reduction in PJI noted in

120

our study is accurate, the cost of PJI management in the United States could be reduced by at

121

approximately $375,000,000 with use of an Aquacel dressing. Therefore, the additional cost

122

associated with routine use of the Aquacel dressing after TJA can be readily justified.

123

We recognize several limitations to our study, such as, principally, its retrospective

124

design on a cohort of consecutive patients. Nonetheless, we were able to include a relatively

125

large number of subjects and all changes in practice, as well as potential confounding factors,

126

were taken into account in a multivariate model to ascertain the independent protective effect of

127

the Aquacel dressing. Our main concern was the confounding effect of intravenous vancomycin

128

prophylaxis and dilute betadine irrigation, two practices we implemented based on recent

129

supportive evidence in the literature [20,21]. However, these two factors did not reach a

130

significant effect on the development of PJI in our current study. This lack of significance is

131

possibly due to the limited number of subjects involved since these two practices were

132

introduced at our institution relatively late in the study period. Finally, our main outcome

133

measurement consisted of PJI occurring within 3 months of surgery. We elected to use the 3-

134

month minimum follow-up, in compliance with the recent recommendations of the Center for

135

Disease Control and Prevention, which uses this period to determine if an infection occurring

136

after surgery could be directly attributed to that procedure or not [22].
7

137

Despite the aforementioned limitations, this case-controlled study demonstrated that the

138

Aquacel Ag Surgical wound dressing with ionic silver significantly reduced the incidence of

139

acute PJI in our cohort of patients. Its systematic use suggests that it would be an effective

140

measure to prevent the occurrence of acute PJI following TJA and thus diminish the significant

141

healthcare costs and patient morbidity of PJI.

142
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Table 1 - List of patient-related and procedure-related factors included in the first step of the
logistic regression model

Demographic factors

Procedure-related factors

Comorbidities

227
228
229
230

Age
Gender
BMI
Joint
Bilateral procedure
OR time
Transfusion need
Type of anesthesia
Length of stay
Aquacel dressing
Dilute betadine irrigation
Smoking status
Frequent alcohol drinking
History of MI
Congestive heart failure
Peripheral vascular disease
Cerebro-vascular disease
Dementia
Chronic pulmonary disease
Connective tissue disease
Coronary artery disease
Peptic ulcer disease
Liver disease
Diabetes mellitus
Chronic renal disease
Malignancy (history, active
disease or metastatic disease)
Rheumatoid disease
Hypertension
Dyslipidemia
Thyroid disease
Psychiatric disease
Anemia
Dysrythmia
History of DVT or PE
GERD
History of steroid treatment
ASA

ASA = American Society of Anaesthesiologistsphysical status classi-cation, BMI= Body Mass
Index, DVT = Deep VeinThrombosis, GERD = Gastro-EsophagealReux Disease, MI =
Myocardial Infarction,OR = Operating Room, PE = PulmonaryEmbolism.
11

Table 2 - Table 2. Factors included in the final logisticregression model with independent
oddsratios and 95% confidence intervals

Odds Ratio
(95% confidence interval)

p-value

Aquacel® dressing use

0.17 (0.05 – 0.53)

0.003

Age

1.09 (1.03 – 1.14)

0.002

Body mass index

1.10 (1.03 - 1.19)

0.006

Former Smoker

3.02 (1.12-8.12)

0.029

Thyroid disease

3.71 (1.42 – 9.67)

0.007

Liver disease

7.03 (1.43-34.60)

0.017

22.22 (1.83 – 269.45)

0.015

History of systemic steroid treatment

231
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